No Cover Image

Journal article 655 views 75 downloads

The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker

Matthew Lawrence Orcid Logo, Vanessa Evans, Janet Whitley, Suresh Gopala Pillai Orcid Logo, Rhodri Williams Orcid Logo, James Coulson, Manju Krishnan, Peter Slade, Kieron Power, Roger H.K. Morris, Adrian Evans

Pharmacology Research and Perspectives, Volume: 10, Issue: 2

Swansea University Authors: Matthew Lawrence Orcid Logo, Vanessa Evans, Janet Whitley, Suresh Gopala Pillai Orcid Logo, Rhodri Williams Orcid Logo, Adrian Evans

  • 60554.pdf

    PDF | Version of Record

    © 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License

    Download (921.87KB)

Check full text

DOI (Published version): 10.1002/prp2.937

Abstract

Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy-eight patients were included in the study, 50 Stroke with AF (AF-S), and 28 AF witho...

Full description

Published in: Pharmacology Research and Perspectives
ISSN: 2052-1707 2052-1707
Published: Wiley 2022
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa60554
first_indexed 2022-07-20T11:56:13Z
last_indexed 2023-01-13T19:20:46Z
id cronfa60554
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-10-31T17:58:03.4488737</datestamp><bib-version>v2</bib-version><id>60554</id><entry>2022-07-20</entry><title>The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker</title><swanseaauthors><author><sid>262d0cae7663ded863d6e2de15757f3c</sid><ORCID>0000-0001-7344-2836</ORCID><firstname>Matthew</firstname><surname>Lawrence</surname><name>Matthew Lawrence</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>a0506225f2491303811176ddf571d03e</sid><ORCID/><firstname>Vanessa</firstname><surname>Evans</surname><name>Vanessa Evans</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>bda7069a6ac3481b27c9986c9bc51e49</sid><ORCID/><firstname>Janet</firstname><surname>Whitley</surname><name>Janet Whitley</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>f567f8d5db61d62ef08e811676fd8430</sid><ORCID>0000-0002-9753-6949</ORCID><firstname>Suresh</firstname><surname>Gopala Pillai</surname><name>Suresh Gopala Pillai</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>642bf793695f412ed932f1ea4d9bc3f1</sid><ORCID>0000-0002-6912-5288</ORCID><firstname>Rhodri</firstname><surname>Williams</surname><name>Rhodri Williams</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>21761f6eb805546a561c9f036e85405b</sid><firstname>Adrian</firstname><surname>Evans</surname><name>Adrian Evans</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2022-07-20</date><deptcode>MEDS</deptcode><abstract>Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy-eight patients were included in the study, 50 Stroke with AF (AF-S), and 28 AF without stroke (AF). Pre- and post-anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df , the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF-S group had a df = 1.70 (&#xB1;0.05) and TGP = 306 (&#xB1;73 s). The AF group had a df = 1.70 &#xB1; 0.05 and TGP = 346 &#xB1; 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood's ability to form stable clots (no change in df ). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.</abstract><type>Journal Article</type><journal>Pharmacology Research and Perspectives</journal><volume>10</volume><journalNumber>2</journalNumber><paginationStart/><paginationEnd/><publisher>Wiley</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2052-1707</issnPrint><issnElectronic>2052-1707</issnElectronic><keywords>Anticoagulation; apixaban; cerebrovascular disease; clot microstructure; gel point and fractal analysis</keywords><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2022</publishedYear><publishedDate>2022-04-01</publishedDate><doi>10.1002/prp2.937</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders>This work was supported by a grant under the ERISTA funding stream which is funded under the Alliance program of both Bristol- Myers Squibb and Pfizer.</funders><projectreference/><lastEdited>2022-10-31T17:58:03.4488737</lastEdited><Created>2022-07-20T12:51:53.2727955</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Matthew</firstname><surname>Lawrence</surname><orcid>0000-0001-7344-2836</orcid><order>1</order></author><author><firstname>Vanessa</firstname><surname>Evans</surname><orcid/><order>2</order></author><author><firstname>Janet</firstname><surname>Whitley</surname><orcid/><order>3</order></author><author><firstname>Suresh</firstname><surname>Gopala Pillai</surname><orcid>0000-0002-9753-6949</orcid><order>4</order></author><author><firstname>Rhodri</firstname><surname>Williams</surname><orcid>0000-0002-6912-5288</orcid><order>5</order></author><author><firstname>James</firstname><surname>Coulson</surname><order>6</order></author><author><firstname>Manju</firstname><surname>Krishnan</surname><order>7</order></author><author><firstname>Peter</firstname><surname>Slade</surname><order>8</order></author><author><firstname>Kieron</firstname><surname>Power</surname><order>9</order></author><author><firstname>Roger H.K.</firstname><surname>Morris</surname><order>10</order></author><author><firstname>Adrian</firstname><surname>Evans</surname><order>11</order></author></authors><documents><document><filename>60554__24672__72d02f3108854aa5929f45170bdf0c7d.pdf</filename><originalFilename>60554.pdf</originalFilename><uploaded>2022-07-20T12:55:58.0634300</uploaded><type>Output</type><contentLength>943998</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-10-31T17:58:03.4488737 v2 60554 2022-07-20 The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker 262d0cae7663ded863d6e2de15757f3c 0000-0001-7344-2836 Matthew Lawrence Matthew Lawrence true false a0506225f2491303811176ddf571d03e Vanessa Evans Vanessa Evans true false bda7069a6ac3481b27c9986c9bc51e49 Janet Whitley Janet Whitley true false f567f8d5db61d62ef08e811676fd8430 0000-0002-9753-6949 Suresh Gopala Pillai Suresh Gopala Pillai true false 642bf793695f412ed932f1ea4d9bc3f1 0000-0002-6912-5288 Rhodri Williams Rhodri Williams true false 21761f6eb805546a561c9f036e85405b Adrian Evans Adrian Evans true false 2022-07-20 MEDS Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy-eight patients were included in the study, 50 Stroke with AF (AF-S), and 28 AF without stroke (AF). Pre- and post-anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df , the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF-S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood's ability to form stable clots (no change in df ). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics. Journal Article Pharmacology Research and Perspectives 10 2 Wiley 2052-1707 2052-1707 Anticoagulation; apixaban; cerebrovascular disease; clot microstructure; gel point and fractal analysis 1 4 2022 2022-04-01 10.1002/prp2.937 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University This work was supported by a grant under the ERISTA funding stream which is funded under the Alliance program of both Bristol- Myers Squibb and Pfizer. 2022-10-31T17:58:03.4488737 2022-07-20T12:51:53.2727955 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Matthew Lawrence 0000-0001-7344-2836 1 Vanessa Evans 2 Janet Whitley 3 Suresh Gopala Pillai 0000-0002-9753-6949 4 Rhodri Williams 0000-0002-6912-5288 5 James Coulson 6 Manju Krishnan 7 Peter Slade 8 Kieron Power 9 Roger H.K. Morris 10 Adrian Evans 11 60554__24672__72d02f3108854aa5929f45170bdf0c7d.pdf 60554.pdf 2022-07-20T12:55:58.0634300 Output 943998 application/pdf Version of Record true © 2022 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License true eng http://creativecommons.org/licenses/by-nc-nd/4.0/
title The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
spellingShingle The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
Matthew Lawrence
Vanessa Evans
Janet Whitley
Suresh Gopala Pillai
Rhodri Williams
Adrian Evans
title_short The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
title_full The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
title_fullStr The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
title_full_unstemmed The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
title_sort The effects of apixaban on clot characteristics in atrial fibrillation: A novel pharmacodynamic biomarker
author_id_str_mv 262d0cae7663ded863d6e2de15757f3c
a0506225f2491303811176ddf571d03e
bda7069a6ac3481b27c9986c9bc51e49
f567f8d5db61d62ef08e811676fd8430
642bf793695f412ed932f1ea4d9bc3f1
21761f6eb805546a561c9f036e85405b
author_id_fullname_str_mv 262d0cae7663ded863d6e2de15757f3c_***_Matthew Lawrence
a0506225f2491303811176ddf571d03e_***_Vanessa Evans
bda7069a6ac3481b27c9986c9bc51e49_***_Janet Whitley
f567f8d5db61d62ef08e811676fd8430_***_Suresh Gopala Pillai
642bf793695f412ed932f1ea4d9bc3f1_***_Rhodri Williams
21761f6eb805546a561c9f036e85405b_***_Adrian Evans
author Matthew Lawrence
Vanessa Evans
Janet Whitley
Suresh Gopala Pillai
Rhodri Williams
Adrian Evans
author2 Matthew Lawrence
Vanessa Evans
Janet Whitley
Suresh Gopala Pillai
Rhodri Williams
James Coulson
Manju Krishnan
Peter Slade
Kieron Power
Roger H.K. Morris
Adrian Evans
format Journal article
container_title Pharmacology Research and Perspectives
container_volume 10
container_issue 2
publishDate 2022
institution Swansea University
issn 2052-1707
2052-1707
doi_str_mv 10.1002/prp2.937
publisher Wiley
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description Atrial fibrillation (AF) is a major risk factor for stroke. We aim to characterize AF patients and the effects of apixaban therapy in terms of clot microstructure using gel point analysis, a novel biomarker. Seventy-eight patients were included in the study, 50 Stroke with AF (AF-S), and 28 AF without stroke (AF). Pre- and post-anticoagulation samples were collected: gel point (GP) analysis was performed to obtain (i) TGP (the time taken to reach the GP or the clot formation time) and (ii) df , the fractal dimension of the clot, a quantification of clot fibrin microstructure at the GP. At baseline, the AF-S group had a df = 1.70 (±0.05) and TGP = 306 (±73 s). The AF group had a df = 1.70 ± 0.05 and TGP = 346 ± 78 s, showing a significantly shortened TGP in the stroke group (p = .008). For both groups, apixaban significantly prolonged TGP, p = .005, but resulted in no change in df. Apixaban prolonged clotting time while having no significant impact on the blood's ability to form stable clots (no change in df ). This indicates that apixaban provides protection from the formation of thrombi by reducing clotting kinetics.
published_date 2022-04-01T15:21:29Z
_version_ 1823321924172775424
score 10.885443

Similar Items